Which Anticoagulant?
The information below is based on European or United Kingdom Summaries of Product Characteristics – approved uses and recommendations for drugs vary by region/country
This table is intended as a quick reference guide only and is not an exhaustive list; refer to local prescribing information for full drug information and use clinical judgement before prescribing
When to use a reduced NOAC dose
Patients receiving anticoagulation with a NOAC should receive a reduced dose in certain clinical situations
© Bayer AG, 2017 | Approval number: PP-XAR-ALL-1742-1
References
The information in this table is taken from the respective Summary of Product Characteristics for the therapies shown, available at the links provided in the table.
See Also
Peripheral Artery Disease: causes and consequences
See Also
Coronary Artery Disease: causes and consequences
Copyright © Bayer AG |
- PP-XAR-ALL-0398-1
Updated date 10/10/2022
This website is intended to provide information to an
international audience outside the USA and UK.
